Patient-reported tolerability of adverse events in phase 1 trials

BACKGROUND: Phase I experts recommend revisiting dose-limiting toxicity (DLT) definition to include chronic and cumulative toxicities induced by new molecularly targeted therapies. Patient’s assessment of late toxicities’ tolerability is, however, unknown. MATERIALS AND METHODS: A prospective survey...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESMO Open
Main Authors: Henon, Clémence, Lissa, Delphine, Paoletti, Xavier, Thibault, Constance, Le Tourneau, Christophe, Lanoy, Emilie, Hollebecque, Antoine, Massard, Christophe, Soria, Jean-Charles, Postel-Vinay, Sophie
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5519806/
https://ncbi.nlm.nih.gov/pubmed/28761740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2016-000148
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados